Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10193696" target="_blank" >RIV/00216208:11110/14:10193696 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/60461373:22340/14:43897828 RIV/00064165:_____/14:10193696
Výsledek na webu
<a href="http://informahealthcare.com/eprint/bJUDhySSw3pF9WIsQQ85/full" target="_blank" >http://informahealthcare.com/eprint/bJUDhySSw3pF9WIsQQ85/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3109/00365513.2013.864784" target="_blank" >10.3109/00365513.2013.864784</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy
Popis výsledku v původním jazyce
Introduction. Circulating tumor cells (CTCs) detection prior to and during therapy is considered as an independent and strong prognostic marker. The present study was designed to isolate and characterize CTCs in peripheral blood of an early breast cancer(BC) patient as a biomarker for monitoring treatments efficacy. Materials and methods. In total, 54 early breast cancer patients undergoing neoadjuvant and/or adjuvant chemotherapy regimens were enrolled into a prospective study. CTC detection in bloodwas performed by AdnaTest BreastCancer (TM) (AdnaGen AG, Germany), which is based on the detection of EpCAM, HER2 and MUC1 specific transcripts in enriched CTC-lysates. Additionally, cDNA from isolated CTCs and PBMC was used for qPCR gene expression analysis of TOP1, TOP2A, CTSD, ST6, CK19 and reference gene actin. Results. We found that CTCs can be detected in the peripheral blood of approximately 31% of early stage breast cancer patients. The presence of CTCs was detected in 36% ER pos
Název v anglickém jazyce
Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy
Popis výsledku anglicky
Introduction. Circulating tumor cells (CTCs) detection prior to and during therapy is considered as an independent and strong prognostic marker. The present study was designed to isolate and characterize CTCs in peripheral blood of an early breast cancer(BC) patient as a biomarker for monitoring treatments efficacy. Materials and methods. In total, 54 early breast cancer patients undergoing neoadjuvant and/or adjuvant chemotherapy regimens were enrolled into a prospective study. CTC detection in bloodwas performed by AdnaTest BreastCancer (TM) (AdnaGen AG, Germany), which is based on the detection of EpCAM, HER2 and MUC1 specific transcripts in enriched CTC-lysates. Additionally, cDNA from isolated CTCs and PBMC was used for qPCR gene expression analysis of TOP1, TOP2A, CTSD, ST6, CK19 and reference gene actin. Results. We found that CTCs can be detected in the peripheral blood of approximately 31% of early stage breast cancer patients. The presence of CTCs was detected in 36% ER pos
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
EB - Genetika a molekulární biologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Scandinavian Journal of Clinical and Laboratory Investigation
ISSN
0036-5513
e-ISSN
—
Svazek periodika
74
Číslo periodika v rámci svazku
2
Stát vydavatele periodika
NO - Norské království
Počet stran výsledku
11
Strana od-do
132-142
Kód UT WoS článku
000334737700008
EID výsledku v databázi Scopus
—